Literature DB >> 15591531

Antiviral treatment initiation costs in chronic hepatitis C.

U Siebert, J Wasem, S Rossol, G Sroczynski, P Aidelsburger, U Ravens-Sieberer, B M Kurth, M P Manns, J G McHutchison, J B Wong.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15591531      PMCID： PMC1774369     

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  10 in total

1.  Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.

Authors:  Z M Younossi; M E Singer; J G McHutchison; K M Shermock
Journal:  Hepatology       Date:  1999-11       Impact factor: 17.425

2.  Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis.

Authors:  J B Wong; R S Koff
Journal:  Ann Intern Med       Date:  2000-11-07       Impact factor: 25.391

3.  Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group.

Authors:  J B Wong; T Poynard; M H Ling; J K Albrecht; S G Pauker
Journal:  Am J Gastroenterol       Date:  2000-06       Impact factor: 10.864

4.  Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C.

Authors:  M Buti; M A Casado; L Fosbrook; J B Wong; R Esteban
Journal:  J Hepatol       Date:  2000-10       Impact factor: 25.083

Review 5.  Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review.

Authors:  J Shepherd; N Waugh; P Hewitson
Journal:  Health Technol Assess       Date:  2000       Impact factor: 4.014

Review 6.  A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C.

Authors:  M Sagmeister; J B Wong; B Mullhaupt; E L Renner
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-05       Impact factor: 2.566

7.  Cost effectiveness of combination therapy for hepatitis C: a decision analytic model.

Authors:  K Stein; W Rosenberg; J Wong
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

8.  Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden.

Authors:  K Sennfält; O Reichard; R Hultkrantz; J B Wong; D Jonsson
Journal:  Scand J Gastroenterol       Date:  2001-08       Impact factor: 2.423

9.  Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

Authors:  U Siebert; G Sroczynski; S Rossol; J Wasem; U Ravens-Sieberer; B M Kurth; M P Manns; J G McHutchison; J B Wong
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

10.  Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs.

Authors:  J B Wong; W G Bennett; R S Koff; S G Pauker
Journal:  JAMA       Date:  1998 Dec 23-30       Impact factor: 56.272
  10 in total
  2 in total

1.  The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.

Authors:  David B Rein; Bryce D Smith; John S Wittenborn; Sarah B Lesesne; Laura D Wagner; Douglas W Roblin; Nita Patel; John W Ward; Cindy M Weinbaum
Journal:  Ann Intern Med       Date:  2011-11-04       Impact factor: 25.391

2.  Predicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis C genotype 1 treatment-naïve patients receiving antiviral therapy.

Authors:  Essè Ifèbi Hervé Akpo; Karin Cerri; Joris Kleintjens
Journal:  Pharmacoeconomics       Date:  2015-04       Impact factor: 4.981
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.